194 related articles for article (PubMed ID: 25013997)
21. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
Underwood LE; Attie KM; Baptista J;
J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
[TBL] [Abstract][Full Text] [Related]
23. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
Bidlingmaier M; Kim J; Savoy C; Kim MJ; Ebrecht N; de la Motte S; Strasburger CJ
J Clin Endocrinol Metab; 2006 Aug; 91(8):2926-30. PubMed ID: 16720652
[TBL] [Abstract][Full Text] [Related]
25. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
26. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
27. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
[TBL] [Abstract][Full Text] [Related]
28. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: a randomised, placebo-controlled study.
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2006 Apr; 16(2):132-42. PubMed ID: 16702006
[TBL] [Abstract][Full Text] [Related]
31. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency.
Biller BM; Ji HJ; Ahn H; Savoy C; Siepl EC; Popovic V; Coculescu M; Roemmler J; Gavrila C; Cook DM; Strasburger CJ
J Clin Endocrinol Metab; 2011 Jun; 96(6):1718-26. PubMed ID: 21411551
[TBL] [Abstract][Full Text] [Related]
32. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects.
Cohen-Barak O; Barkay H; Rasamoelisolo M; Butler K; Yamada K; Bassan M; Yoon E; Spiegelstein O
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):331-342. PubMed ID: 27489211
[TBL] [Abstract][Full Text] [Related]
34. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
Hoffman AR; Kuntze JE; Baptista J; Baum HB; Baumann GP; Biller BM; Clark RV; Cook D; Inzucchi SE; Kleinberg D; Klibanski A; Phillips LS; Ridgway EC; Robbins RJ; Schlechte J; Sharma M; Thorner MO; Vance ML
J Clin Endocrinol Metab; 2004 May; 89(5):2048-56. PubMed ID: 15126520
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: a randomized, placebo-controlled trial.
Chihara K; Fujieda K; Shimatsu A; Miki T; Tachibana K
Growth Horm IGF Res; 2010 Jun; 20(3):205-11. PubMed ID: 20176498
[TBL] [Abstract][Full Text] [Related]
37. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.
de Schepper J; Rasmussen MH; Gucev Z; Eliakim A; Battelino T
Eur J Endocrinol; 2011 Sep; 165(3):401-9. PubMed ID: 21724838
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
39. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD).
Péter F; Bidlingmaier M; Savoy C; Ji HJ; Saenger PH
J Clin Endocrinol Metab; 2012 Feb; 97(2):400-7. PubMed ID: 22162481
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial.
Conchillo M; de Knegt RJ; Payeras M; Quiroga J; Sangro B; Herrero JI; Castilla-Cortazar I; Frystyk J; Flyvbjerg A; Yoshizawa C; Jansen PL; Scharschmidt B; Prieto J
J Hepatol; 2005 Oct; 43(4):630-6. PubMed ID: 16024131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
